Results 91 to 100 of about 244,396 (239)

IFAA Recommendations for good practice for the donation and anatomical study of human remains (revised 2026)

Anatomical Sciences Education, EarlyView.
Abstract The study of human anatomy is foundational to education and research in the anatomical and health sciences. In 2012, the International Federation of Associations of Anatomists (IFAA) first published Recommendations to promote ethical practice in the acquisition of human remains for this purpose.
D. Gareth Jones, Thomas H. Champney, Sabine Hildebrandt, Andreas Winkelmann, Brendon Billings, Sanjib K. Ghosh, İlke Ali Gürses, Diogo Pais, Brandi Schmitt, Jon Cornwall   +9 more
wiley   +1 more source

Medical students' perspectives on body donation to science within the Italian context

Anatomical Sciences Education, EarlyView.
Abstract Body donation is essential for medical education and research, supporting anatomical training and clinical competence. In Italy, national data on awareness of the legislation regulating body donation and factors shaping donation‐related decisions among healthcare trainees remain limited. This study investigated knowledge of the legal framework,
Antonietta Fazio, Giulio Vara, Veronica Moretti, Annalisa Plava, Anna Maria Billi, Alessandra Ruggeri, Giulia Adalgisa Mariani, Marilisa Quaranta, Simone Lodi, Cecilia Acuti Martellucci, Maria Alessandra Sotgiu, Valentina Di Felice, Sergio Castorina, Guido Carpino, Veronica Macchi, Rita Rezzani, Mario Rende, Andrea Montella, Lucio Cocco, Lucia Manzoli, Stefano Ratti   +20 more
wiley   +1 more source

From classroom to clinic: Evaluating the educational utility of two Thiel embalming methods

Anatomical Sciences Education, EarlyView.
Abstract Over three decades since its introduction, the Thiel embalming method remains a widely used and praised technique in anatomical education and clinical training. This study compared for the first time the Thiel original protocol (TO) and a Modified version (TM) across user groups—undergraduate medical students, student demonstrators in anatomy,
Veronica Antipova, Martin Siwetz, Simone Manhal, Niels Hammer   +3 more
wiley   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Regulatory Science: exploring an emerging scientific discipline in health care

Frontiers in Medicine
Regulatory Science has gained increasing prominence in the regulatory community, yet its character as a scientific discipline remains insufficiently clarified.
Laura Volpi, Laura Volpi, Michael D’Agosto, Tom Melvin, Barbara Sickmüller, Julian S. Thimm   +5 more
doaj   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Costs of treating type 2 diabetes mellitus and its complications

Biotechnology & Biotechnological Equipment
The major driver of the costs of treating patients with diabetes mellitus type 2 (DM2) is its complications, which in developing countries are a consequence of poor glycemic control due to the low availability of novel, innovative antidiabetic drugs.
Nemanja Petrović, Miloš Milosavljević, Refet Gojak, Miralem Đešević, Dragana Lakić, Ivana Stević, Slobodan Janković   +6 more
doaj   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source